SCHEMBL4209151

SCHEMBL4209151

Cc1ccccc1Nc1cc(-c2cccc(Cl)c2)ccc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 6/20 0.55
FABP4 P15090 4/20 0.54
HCAR2 Q8TDS4 1/20 0.52
AKR1C3 P42330 3/20 0.51
MEN1 O00255 2/20 0.51
LMNA P02545 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 2/20 0.51
PTGS2 P35354 2/20 0.51
KMT2A Q03164 2/20 0.51
HIF1A Q16665 2/20 0.51
AKR1C2 P52895 2/20 0.51
AKR1B10 O60218 1/20 0.51
TRPA1 O75762 1/20 0.51
ABCB11 O95342 1/20 0.51
DHFR P00374 1/20 0.51
MPO P05164 1/20 0.51
CHRM1 P11229 1/20 0.51
AKR1B1 P15121 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4223433 0.89 FABP4 (0.58) ACLYFABP4AKR1C3MEN1LMNA
SCHEMBL4222643 0.86 FABP4 (0.56) ACLYFABP4HCAR2AKR1C3MEN1
SCHEMBL4211160 0.84 ACLY (0.60) ACLYFABP4HCAR2AKR1C3AKR1C2
SCHEMBL4225722 0.80 AKR1C3 (0.64) ACLYHCAR2AKR1C3MEN1LMNA
SCHEMBL2276321 0.79 ACLY (0.56) ACLYHCAR2DCLRE1BSUCNR1GRIK1
SCHEMBL10024224 0.79 DCLRE1B (0.61) ACLYHCAR2AKR1C2AKR1C1DCLRE1B
SCHEMBL4216661 0.78 FTO (0.58) ACLYFABP4AKR1C3MEN1LMNA
SCHEMBL6481477 0.78 KDM4E (0.56) FABP4AKR1C3MEN1LMNACYP1A2
SCHEMBL11608819 0.77 FABP4 (0.56) FABP4AKR1C3MEN1LMNACYP1A2
SCHEMBL4186922 0.77 AKR1C3 (0.60) FABP4AKR1C3MEN1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 ACLY 430/4885FABP4 2976/4885HCAR2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.